Citadel Advisors
SLGC

Citadel Advisors’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Citadel Advisors’s Portfolio SLGC Stock Details SLGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-600
Closed -$1.52K – 15850
2023
Q4 		$1.52K Sell
600
-51,000
-99% -$119K ﹤0.01% 13811
2023
Q3 		$123K Sell
51,600
-3,200
-6% -$7.08K ﹤0.01% 10628
2023
Q2 		$127K Buy
54,800
+28,700
+110% +$81K ﹤0.01% 10572
2023
Q1 		$66.6K Buy
26,100
+13,000
+99% +$37.2K ﹤0.01% 11801
2022
Q4 		$32.9K Sell
13,100
-2,300
-15% -$6.42K ﹤0.01% 12626
2022
Q3 		$45K Sell
15,400
-15,600
-50% -$65.7K ﹤0.01% 11713
2022
Q2 		$140K Buy
+31,000
New +$184K ﹤0.01% 11059

Citadel Advisors's SLGC Position: Q1 2024 in Review

Citadel Advisors sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 50,798 shares — an estimated $129K sold.

Citadel Advisors first reported a position in SLGC in Q3 2021 and held it in 9 quarters. The position peaked at $16.1M in Q1 2022. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

  • Citadel Advisors reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 50,798 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $129K.
  • Citadel Advisors first reported a position in SomaLogic, Inc. Class A Common Stock in Q3 2021 and held it in 9 quarters.
  • Citadel Advisors's SomaLogic, Inc. Class A Common Stock position peaked at $16.1M in Q1 2022.
  • 0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.